Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Lexicon Pharmaceuticals / Equity Bottom-Up

<ul><li>Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing treatments for serious diseases, recently shared their third-quarter 2024 financial results and provided business updates.</li><li>Among their key areas of activity are their drug programs including INPEFA, ZYNQUISTA, LX9211, and LX9851.</li><li>This quarter marked significant developments for Lexicon as they continued their strategic initiatives and focused on advancing their pipeline.</li></ul>

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing treatments for serious diseases, recently shared their third-quarter 2024 financial results and provided business updates.Among their key areas of activity are their drug programs including INPEFA, ZYNQUISTA, LX9211, and LX9851.This quarter marked significant developments for Lexicon as they continued their strategic initiatives and focused on advancing their pipeline.

Lexicon’s FDA Rejection, Layoffs, and Nasdaq Delisting Threat: Can It Get Acquired?

United States

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company.  The Company researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lexicon Pharmaceuticals (LXRX US)

Lexicon’s FDA Rejection, Layoffs, and Nasdaq Delisting Threat: Can It Get Acquired?

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing treatments for serious diseases, recently shared their third-quarter...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)